二仙汤联合枸橼酸他莫昔芬片治疗乳腺囊性增生病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R271.44

基金项目:


Clinical Study on Erxian Tang Combined with Tamoxifen Citrate Tablets on Breast Cystic Hyperplasia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察二仙汤联合枸橼酸他莫昔芬片治疗乳腺囊性增生病的临床疗效。方法:选取82 例乳腺囊性增生病患者,按随机数字表法分为治疗组、对照组各41 例。对照组采用枸橼酸他莫昔芬片治疗,治疗组在对照组基础上加用二仙汤治疗。2 组疗程均为3 个月经周期。比较2 组临床疗效及不良反应发生率,观察2 组治疗前后局部症状评分及血清内分泌激素[雌二醇(E2)、孕酮(P)、催乳素(PRL)]水平的变化,比较2 组复发率。结果:治疗后,2 组乳房疼痛、乳头溢液、囊肿大小、囊肿数量的评分均较治疗前下降,差异均有统计学意义(P<0.05);治疗后,治疗组乳房疼痛、乳头溢液、囊肿大小、囊肿数量评分均低于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组血清PRL、E2 水平均较治疗前下降,血清P 水平均较治疗前上升,差异均有统计学意义(P<0.05);治疗后,治疗组血清PRL、E2 水平均低于对照组,血清P 水平高于对照组,差异均有统计学意义(P<0.05)。治疗组临床疗效总有效率为92.7%,对照组总有效率为75.6%,2 组比较,差异有统计学意义(P<0.05)。治疗组复发率为7.9%,对照组复发率为25.8%,2 组比较,差异有统计学意义(P<0.05)。治疗组不良反应发生率为5.3%,对照组不良反应发生率为25.8%,2 组比较,差异有统计学意义(P<0.05)。结论:二仙汤联合枸橼酸他莫昔芬片治疗乳腺囊性增生病疗效较好,可调节内分泌激素紊乱状态,缓解患者局部症状,降低复发率,用药安全性较高。

    Abstract:

    Abstract: Objective: To observe the clinical effect of Erxian tang combined with tamoxifen citrate tablets on breast cystic hyperplasia. Methods: A total of 82 patients with breast cystic hyperplasia were divided into the treatment group and the control group according to the random number table method,with 41 cases in each group. The control group was treated with tamoxifen citrate tablets, and the treatment group was additionally treated with Erxian tang based on the treatment of the control group. Both groups were treated for three menstrual cycles. The clinical effects and incidences of adverse reactions were compared between the two groups. Before and after treatment,the changes of scores of local symptoms and levels of serum endocrine hormones, including estradiol(E2), progesterone(P) and prolactin(PRL), in the two groups were observed. The recurrence rates were compared between the two groups. Results: After treatment,the scores of breast pain,nipple discharge,size of cysts and number of cysts in the two groups were decreased when compared with those before treatment, differences being significant(P< 0.05); after treatment, the above scores in the treatment group were lower than those in the control group,differences being significant(P<0.05). After treatment,the levels of serum PRL and E2 in the two groups were decreased when compared with those before treatment, and the levels of serum P were increased,differences being significant(P<0.05);after treatment,the levels of serum PRL and E2 in the treatment group were lower than those in the control group, and the level of serum P was higher, differences being significant(P<0.05). The total clinical effective rate was 92.7% in the treatment group, and was 75.6% in the control group, the difference being significant(P<0.05). The recurrence rate was 7.9% in the treatment group, and was 25.8% in the control group, the difference being significant(P< 0.05). The incidence of adverse reactions was 5.3% in the treatment group,and was 25.8% in the control group, the difference being significant(P<0.05). Conclusion: The therapy of Erxian tang combined with tamoxifen citrate tablets has a good curative effect on breast cystic hyperplasia, which can regulate the disorder states of endocrine hormones, alleviate the local symptoms of patients, and reduce the recurrence rates,with high administration safety.

    参考文献
    相似文献
    引证文献
引用本文

张华君.二仙汤联合枸橼酸他莫昔芬片治疗乳腺囊性增生病临床研究[J].新中医,2022,54(13):78-82

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-07-07
  • 出版日期:
文章二维码